Topic:

Cancer Vaccines

Latest Headlines

Latest Headlines

Celldex glioblastoma vaccine extends survival in Phase II

In a Phase II trial, Celldex Therapeutics' cancer vaccine rindopepimut, or Rintega, helped recurrent glioblastoma patients who took it with Roche's Avastin survive a median of 3.2 months longer than patients who took Avastin alone. 

Dendreon bankruptcy weighs on cancer vaccine field

Ever since Dendreon's lackluster Provenge launch, the Washington-based biotech's failures have cast a pall over the troubled cancer vaccine field. And the company's bankruptcy won't help with that.

Dendreon's Provenge at the center of CMS insider trading probe

The SEC is investigating whether officials at the Center for Medicare and Medicaid Services tipped off a policy research group about the agency's review of Dendreon's cancer vaccine, Provenge, The Wall Street Journal reports.

Are personalized approaches the solution for a troubled cancer vaccine field?

Cancer vaccine developers have seen their fair share of disappointments, and failures have spurred some companies to test their treatments in smaller patient subpopulations. Now, researchers are narrowing their focus even further as they gear up to trial personalized cancer vaccines.

Cancer vaccine partners J&J, Aduro add $817M pact

Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.

Immunotherapy combos could provide a new path forward for troubled cancer vaccine field

When John Vansteenkiste of Belgium University Hospitals Leuven reported the full results of GlaxoSmithKline's MAGE-A3 failure at the European Society of Medical Oncology's annual congress last weekend, he wasn't the first to outline a cancer vaccine flop. But he did offer a way out from under the dark cloud hanging over the field, and it's one that some cancer vaccine makers are already embracing.

CureVac inks lung cancer vaccine deal with Boehringer for up to $600M

CureVac has made its second notable deal with Big Pharma this year, this time partnering with Boehringer Ingelheim to offer its investigational lung cancer vaccine in a $45 million deal with potential milestone payments of up to $556 million.

Asterias, Cancer Research UK partner on lung cancer vaccine trial

Asterias Biotherapeutics, a subsidiary of California-based BioTime, is teaming up with nonprofit Cancer Research UK to trial an immunotherapy vaccine to treat patients with non-small cell lung cancer.

Merck KGaA calls it quits on cancer vaccine--again

After a failed attempt to revive its late-stage program for Stimuvax, Merck KGaA is once again throwing in the towel on the cancer vaccine. The German company's biopharma division will cut its two monotherapy studies in the wake of another recent trial failure in Japan, it said late last week.

Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients

A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.